-
公开(公告)号：US20120251531A1
公开(公告)日：2012-10-04
申请号：US13431489
申请日：2012-03-27
IPC分类号： A61K39/395 , C07K19/00 , C07K16/28
CPC分类号： C07K16/2896 , C07K16/00 , C07K2317/52 , C07K2317/56 , C07K2317/71 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/92 , C07K2319/30 , Y10S435/81
摘要： The invention relates to engineered polypeptides comprising Fc variants and their uses. More specifically, Fc variants are described exhibiting reduced effector function. These variants cause a benefit for a patient suffering from a disease which could be treated with an antibody for which it is desirable to reduce the effector function elicited by antibodies.
摘要翻译： 本发明涉及包含Fc变体及其用途的工程化多肽。 更具体地，描述了表现出降低的效应子功能的Fc变体。 这些变体对患有可以用希望减少由抗体引起的效应子功能的抗体治疗的疾病患者造成益处。
-
公开(公告)号：US08969526B2
公开(公告)日：2015-03-03
申请号：US13431489
申请日：2012-03-27
IPC分类号： C07K16/00 , A61K39/395 , A61K39/40 , C07K1/00
CPC分类号： C07K16/2896 , C07K16/00 , C07K2317/52 , C07K2317/56 , C07K2317/71 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/92 , C07K2319/30 , Y10S435/81
摘要： The invention relates to engineered polypeptides comprising Fc variants and their uses. More specifically, Fc variants are described exhibiting reduced effector function. These variants cause a benefit for a patient suffering from a disease which could be treated with an antibody for which it is desirable to reduce the effector function elicited by antibodies.
摘要翻译： 本发明涉及包含Fc变体及其用途的工程化多肽。 更具体地，描述了表现出降低的效应子功能的Fc变体。 这些变体对患有可以用希望减少由抗体引起的效应子功能的抗体治疗的疾病患者造成益处。
-
3.发明授权Multispecific antibodies comprising full length antibodies and single chain fab fragments 有权包含全长抗体和单链Fab片段的多特异性抗体公开(公告)号：US09382323B2
公开(公告)日：2016-07-05
申请号：US12750748
申请日：2010-03-31
申请人： Ulrich Brinkmann , Peter Bruenker , Rebecca Croasdale , Christian Klein , Erhard Kopetzki , Ekkehard Moessner , Joerg Thomas Regula , Juergen Michael Schanzer , Jan Olaf Stracke , Pablo Umana
发明人： Ulrich Brinkmann , Peter Bruenker , Rebecca Croasdale , Christian Klein , Erhard Kopetzki , Ekkehard Moessner , Joerg Thomas Regula , Juergen Michael Schanzer , Jan Olaf Stracke , Pablo Umana
CPC分类号： C07K16/2863 , A61K2039/505 , C07K16/00 , C07K16/468 , C07K2317/21 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/626 , C07K2317/64 , C07K2317/73 , C07K2319/00
摘要： The present invention relates to multispecific, especially bispecific antibodies comprising full length antibodies and single chain Fab fragments, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
摘要翻译： 本发明涉及包含全长抗体和单链Fab片段的多特异性，特别是双特异性抗体，其制备方法，含有该抗体的药物组合物及其用途。
-
公开(公告)号：US20120244112A1
公开(公告)日：2012-09-27
申请号：US13367843
申请日：2012-02-07
申请人： Oliver Ast , Peter Bruenker , Anne Freimoser-Grundschober , Sylvia Herter , Thomas U. Hofer , Ralf Hosse , Christian Klein , Ekkehard Moessner , Valeria G. Nicolini , Pablo Umana
发明人： Oliver Ast , Peter Bruenker , Anne Freimoser-Grundschober , Sylvia Herter , Thomas U. Hofer , Ralf Hosse , Christian Klein , Ekkehard Moessner , Valeria G. Nicolini , Pablo Umana
CPC分类号： C07K16/40 , A61K38/2013 , A61K47/6813 , A61K47/6849 , A61K47/6871 , A61K47/6891 , A61K2039/505 , C07K14/55 , C07K16/30 , C07K2319/00
摘要： The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
摘要翻译： 本发明一般涉及对IL-2受体的α亚基表现出降低的亲和力的突变白细胞介素-2多肽，用作免疫治疗剂。 此外，本发明涉及包含所述突变型IL-2多肽，编码突变型IL-2多肽或免疫缀合物的多核苷酸分子以及包含该多核苷酸分子的载体和宿主细胞的免疫缀合物。 本发明还涉及用于产生突变型IL-2多肽或免疫缀合物的方法，包含其的药物组合物及其用途。
-
公开(公告)号：US20110052582A1
公开(公告)日：2011-03-03
申请号：US12868845
申请日：2010-08-26
申请人： Johannes Auer , Birgit Bossenmaier , Guy Georges , Alexander Lifke , Ekkehard Moessner , Gerhard Niederfellner
发明人： Johannes Auer , Birgit Bossenmaier , Guy Georges , Alexander Lifke , Ekkehard Moessner , Gerhard Niederfellner
IPC分类号： A61K39/395 , C07K16/18 , C07H21/00 , C12N15/63 , C12N5/10 , C12N1/00 , C12P21/02 , A61P35/00
CPC分类号： C07K16/30 , C07K16/2896 , C07K2317/24 , C07K2317/41 , C07K2317/56 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/75 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
摘要翻译： 本发明涉及针对人CDCP1（抗CDCP1抗体）的人源化抗体，其制备方法，含有所述抗体的药物组合物及其用途。
-
公开(公告)号：US20100256340A1
公开(公告)日：2010-10-07
申请号：US12752216
申请日：2010-04-01
申请人： Ulrich Brinkmann , Rebecca Croasdale , Eike Hoffmann , Christian Klein , Ekkehard Moessner , Juergen Michael Schanzer , Claudio Sustmann , Pablo Umana
发明人： Ulrich Brinkmann , Rebecca Croasdale , Eike Hoffmann , Christian Klein , Ekkehard Moessner , Juergen Michael Schanzer , Claudio Sustmann , Pablo Umana
CPC分类号： C07K16/00 , C07K16/2863 , C07K16/32 , C07K2317/24 , C07K2317/31 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2319/00
摘要： The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
摘要翻译： 本发明涉及三价，双特异性抗体，其制备方法，含有抗体的药物组合物及其用途。
-
公开(公告)号：US09011847B2
公开(公告)日：2015-04-21
申请号：US13205743
申请日：2011-08-09
申请人： Marina Bacac , Anne Freimoser-Grundschober , Ralf Hosse , Christian Klein , Ekkehard Moessner , Valeria G. Nicolini , Pablo Umaña
发明人： Marina Bacac , Anne Freimoser-Grundschober , Ralf Hosse , Christian Klein , Ekkehard Moessner , Valeria G. Nicolini , Pablo Umaña
IPC分类号： A61K39/395 , C07K16/40
CPC分类号： C07K16/40 , A61K47/6871 , A61K51/1075 , C07K16/30 , C07K2317/21 , C07K2317/33 , C07K2317/41 , C07K2317/55 , C07K2317/565 , C07K2317/732 , C07K2317/92
摘要： The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.
摘要翻译： 本发明提供了抗成纤维细胞活化蛋白（FAP）的抗体及其使用方法。
-
公开(公告)号：US08394928B2
公开(公告)日：2013-03-12
申请号：US12868845
申请日：2010-08-26
申请人： Johannes Auer , Birgit Bossenmaier , Guy Georges , Alexander Lifke , Ekkehard Moessner , Gerhard Niederfellner
发明人： Johannes Auer , Birgit Bossenmaier , Guy Georges , Alexander Lifke , Ekkehard Moessner , Gerhard Niederfellner
IPC分类号： C12P21/08
CPC分类号： C07K16/30 , C07K16/2896 , C07K2317/24 , C07K2317/41 , C07K2317/56 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/75 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
摘要翻译： 本发明涉及针对人CDCP1（抗CDCP1抗体）的人源化抗体，其制备方法，含有所述抗体的药物组合物及其用途。
-
9.发明申请Method and Constructs for the pH Dependent Passage of the Blood-brain-barrier 审中-公开血脑屏障pH依赖通道的方法和结构公开(公告)号：US20120282176A1
公开(公告)日：2012-11-08
申请号：US13450240
申请日：2012-04-18
申请人： Bernd Bohrmann , Per-Ola Freskgard , Adrian Hugenmatter , Erhard Kopetzki , Ekkehard Moessner , Jens Niewoehner , Hadassah Sumum Sade , Pablo Umaña
发明人： Bernd Bohrmann , Per-Ola Freskgard , Adrian Hugenmatter , Erhard Kopetzki , Ekkehard Moessner , Jens Niewoehner , Hadassah Sumum Sade , Pablo Umaña
IPC分类号： A61K39/395 , G01N33/53 , A61K51/10 , A61K9/127 , A61P25/00 , C07K19/00 , C12N9/96 , B82Y5/00
CPC分类号： C07K16/2881 , A61K2039/54 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30
摘要： Herein is reported a fusion polypeptide comprising i) at least one binding site, e.g. which comprises an antibody heavy chain variable domain and an antibody light chain variable domain, and which binds to an internalizing cell surface receptor, and ii) at least one pharmaceutically active compound, whereby the EC50-value of the binding pair that binds to an internalizing cell surface receptor determined at pH 5.5 is higher than the EC50-value of the same binding pair determined at pH 7.4 and its use for delivering a pharmaceutically active compound across the blood-brain-barrier.
摘要翻译： 本文报道了融合多肽，其包含i）至少一个结合位点， 其包含抗体重链可变结构域和抗体轻链可变结构域，并结合内化细胞表面受体，和ii）至少一种药学活性化合物，其中结合对的EC 50值与内化 在pH5.5下测定的细胞表面受体高于在pH7.4下测定的相同结合对的EC50值，以及用于在血脑屏障上递送药物活性化合物的用途。
-
公开(公告)号：US20120251529A1
公开(公告)日：2012-10-04
申请号：US13408171
申请日：2012-02-29
申请人： Thomas U. Hofer , Ralf Hosse , Ekkehard Moessner , Pablo Umana
发明人： Thomas U. Hofer , Ralf Hosse , Ekkehard Moessner , Pablo Umana
CPC分类号： C07K16/42 , A61K39/39566 , A61K45/06 , A61K2039/505 , A61N5/10 , C07K16/3007 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2317/732 , C07K2317/92 , C07K2317/94
摘要： The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.
摘要翻译： 本发明提供了结合膜结合CEA的抗原结合分子（ABM），其包括具有改善的治疗性质的ABM及其使用方法。
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.042 秒)
